WONDER WHY DODI HANDY DID NOT DISCLOSE IN ELITES PROFILE THAT J.M. DUTTON HAS WROTE SPECULATIVE BUY REPORTS FOR THE SOME REAL SCAMMY COMANIES AND REQUIRES A $25,000 fee to write a report.
efcg.net
J.M. Dutton analyst Gerald F. LaKarnafeaux, CFA, noted in an 8-page report released in February 2002, “We concur in the expectation that private or thinly traded healthcare businesses can be purchased at attractive valuation levels by public companies using marketable stock as currency. Health Sciences Group has demonstrated the validity of the concept in these initial transactions.” The report, issuing a Speculative Buy Recommendation, assigned a $5.75-$6.50 price target in 12 months for HESG.
Huge Revenue Opportunities: In 2000, the non-prescription, over-the-counter drug markets generated $19 billion in annual sales in the U.S. and $49 billion in annual sales on a global basis, according to the International Trade Commission. Additionally, according to the Nutritional Business Journal, the U.S. nutraceutical and dietary supplement market generated $16.8 billion in retail sales in the year 2000.
Access To Growth Capital: Slow IPO market has promoted an environment ripe for consolidation of profitable healthcare-related companies seeking access to growth capital, which Health Sciences can provide. Management is currently reviewing a steady supply of quality acquisition candidates and strategic funding sources and looks to complete 1-2 additional acquisitions in 2002. Currently, the applicable nutraceutical and overlapping non-prescription pharmaceutical market segments within the United States represent an estimated total annual revenue opportunity in excess of $35.8 billion, according to the US International Trade Commission and Nutritional Business Journal. Within this highly fragmented market lie a number of identified companies that are believed to be limited in their current value recognition due to constraints of narrow capital resources, limited operational management expertise, poor access to product distribution channels, and inadequate application of proprietary intellectual property. These companies are believed to represent prime targets for Health Sciences’ acquisition and integration strategy.
Solid Management Team: Health Sciences’ management team has significant experience in mergers and acquisitions, capital formation, business valuations and operations management. The management team is also presently evaluating a number of prospective and highly qualified candidates for appointment to its Board of Directors and Advisory Board. |
